In vivo hyperexpression of transforming growth factor-beta1 in mice: stimulation by cyclosporine. Academic Article uri icon

Overview

abstract

  • BACKGROUND: We have demonstrated that cyclosporine (CsA) stimulates transforming growth factor (TGF) beta1 expression in vitro and that growth of mammalian cells can be arrested by CsA via a TGF-beta1-dependent mechanism. Herein, we have explored whether CsA stimulates TGF-beta1 hyperexpression in vivo. METHODS: Four groups of B6AF1 mice were studied: group 1, control; group 2, CsA pretreatment; group 3, anti-CD3 monoclonal antibody pretreatment; and group 4, CsA plus anti-CD3 pretreatment. RESULTS: CsA pretreatment augmented TGF-beta1 protein expression and increased intrarenal display of TGF-beta1 mRNA. This heightened TGF-beta1 expression was associated with an impaired T cell proliferative response. CONCLUSIONS: Our observations, together, advance the hypothesis that CsA might function in vivo as an immunosuppressant not only by inhibiting the expression of proinflammatory cytokines (e.g., interleukin 2), but also by stimulating the expression of TGF-beta1, a potent immunosuppressive cytokine. Moreover, prevention of TGF-beta1 hyperexpression might prevent CsA-associated renal fibrosis, as TGF-beta1 is a fibrogenic cytokine.

publication date

  • April 15, 1997

Research

keywords

  • Antibodies, Monoclonal
  • CD3 Complex
  • Cyclosporine
  • Immunosuppressive Agents
  • Transforming Growth Factor beta

Identity

Scopus Document Identifier

  • 0030903515

Digital Object Identifier (DOI)

  • 10.1097/00007890-199704150-00026

PubMed ID

  • 9112364

Additional Document Info

volume

  • 63

issue

  • 7